Lipella Pharmaceuticals Inc., of Pittsburgh, Pa., said a physician-initiated, double-blind, randomized, placebo-controlled trial comparing the intravesical instillation of a topical botulinum toxin type A formulation (LP-09) to placebo in 24 subjects diagnosed with overactive bladder (OAB) showed significant reductions in both urinary urgency and urinary frequency.